Post Profile

Roche's Alecensa wins EU panel's nod against mutated lung cancer

ZURICH (Reuters) - Swiss drugmaker Roche's Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency (ESA) experts panel said on Friday.
read more


Related Posts

Roche's Alecensa bests Pfizer's Xalkori in lung cancer trial

Health : Reuters: Health

CHICAGO (Reuters) - Roche Holding AG's Alecensa halted the spread of lung cancer for a median of 15 months longer than treatment with rival Pfizer Inc's Xalkori with fewer side effects, according to trial results presented on Monday...

Novartis posts a win, Roche a flop in skin cancer trials

Health : Reuters: Health

ZURICH/MADRID (Reuters) - Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient gro...

Roche's lung cancer drug wins U.S. approval

Health : Reuters: Health

(Reuters) - Swiss drugmaker Roche Holding AG's new immunotherapy, Tecentriq, won approval on Tuesday from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb's position...

Roche's Alecensa notches trial win against Pfizer's Xalkori

Health : Reuters: Health

ZURICH (Reuters) - Roche's Alecensa kept people with a specific lung cancer alive longer without their disease progressing than Pfizer's Xalkori, the Swiss drugmaker said on Monday, as it seeks to move in on the U.S. company's share...

Roche's Tecentriq receives positive opinion from EU medicines agency

Health : Reuters: Health

ZURICH (Reuters) - A European Medicines Agency (EMA) panel said on Friday it has recommended Roche's immunotherapy Tecentriq as a treatment for advanced bladder and lung cancer, setting the stage for European Commission approval thi...


Copyright © 2016 Regator, LLC